10/620559

```
=> d his

     (FILE 'HOME' ENTERED AT 14:13:23 ON 26 JAN 2004)

     FILE 'REGISTRY' ENTERED AT 14:13:33 ON 26 JAN 2004
L1                STRUCTURE UPLOADED
L2              5 S L1
L3             85 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:14:35 ON 26 JAN 2004
L4              6 S L3

     FILE 'BEILSTEIN' ENTERED AT 14:15:47 ON 26 JAN 2004
L5              0 S L1
L6              0 S L1 SSS FULL

     FILE 'MARPAT' ENTERED AT 14:16:20 ON 26 JAN 2004
L7              0 S L3
L8             14 S L3 SSS FULL

     FILE 'CAPLUS' ENTERED AT 14:16:57 ON 26 JAN 2004
L9             14 S L8

=> s l9 not l4
L10             8 L9 NOT L4
```

C:\STNEXP4\QUERIES\10620559.str





chain nodes :
101
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48
49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71
72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89
chain bonds :
8-101
ring bonds :
1-2 1-5 2-3 2-7 3-4 4-5 5-6 6-8 7-8 9-10 9-13 10-11 10-34 11-12 11-37 12-13
14-15 14-18 15-16 15-38 16-17 16-41 17-18 19-20 19-23 20-21 20-42 21-22 21-45
22-23 24-25 24-29 25-26 26-27 27-28 28-29 28-30 29-33 30-31 31-32 32-33 34-35
35-36 36-37 38-39 39-40 40-41 42-43 43-44 44-45 46-47 46-50 47-48 47-64 48-49
48-67 49-50 51-52 51-55 52-53 52-68 53-54 53-71 54-55 56-57 56-60 57-58 58-59
59-60 59-61 60-63 61-62 62-63 64-65 65-66 66-67 68-69 69-70 70-71 72-73 72-76
73-74 74-75 75-76 75-77 76-79 77-78 78-79 80-81 80-84 81-82 82-83 83-84 85-86
85-89 86-87 87-88 88-89
exact/norm bonds :
1-2 1-5 2-3 2-7 3-4 4-5 5-6 6-8 7-8 8-101 9-10 9-13 11-12 12-13 14-15 14-18
16-17 17-18 19-20 19-23 21-22 22-23 46-47 46-50 48-49 49-50 51-52 51-55 53-54
54-55 56-57 56-60 57-58 58-59 59-60 59-61 60-63 61-62 62-63 72-73 72-76 73-74
74-75 75-76 75-77 76-79 77-78 78-79 80-81 80-84 81-82 82-83 83-84 85-86 85-89
86-87 87-88 88-89
normalized bonds :
10-11 10-34 11-37 15-16 15-38 16-41 20-21 20-42 21-45 24-25 24-29 25-26 26-27
27-28 28-29 28-30 29-33 30-31 31-32 32-33 34-35 35-36 36-37 38-39 39-40 40-41
42-43 43-44 44-45 47-48 47-64 48-67 52-53 52-68 53-71 64-65 65-66 66-67 68-69
69-70 70-71

G1:[*1],[*2],[*3],[*4],[*5],[*6],[*7],[*8],[*9],[*10]

Match level :

1:Atom	2:Atom	3:Atom	4:Atom	5:Atom	6:Atom	7:Atom	8:Atom	9:Atom	10:Atom	11:Atom
12:Atom	13:Atom	14:Atom	15:Atom	16:Atom	17:Atom	18:Atom	19:Atom	20:Atom	21:Atom	
22:Atom	23:Atom	24:Atom	25:Atom	26:Atom	27:Atom	28:Atom	29:Atom	30:Atom	31:Atom	
32:Atom	33:Atom	34:Atom	35:Atom	36:Atom	37:Atom	38:Atom	39:Atom	40:Atom	41:Atom	
42:Atom	43:Atom	44:Atom	45:Atom	46:Atom	47:Atom	48:Atom	49:Atom	50:Atom	51:Atom	
52:Atom	53:Atom	54:Atom	55:Atom	56:Atom	57:Atom	58:Atom	59:Atom	60:Atom	61:Atom	
62:Atom	63:Atom	64:Atom	65:Atom	66:Atom	67:Atom	68:Atom	69:Atom	70:Atom	71:Atom	
72:Atom	73:Atom	74:Atom	75:Atom	76:Atom	77:Atom	78:Atom	79:Atom	80:Atom	81:Atom	
82:Atom	83:Atom	84:Atom	85:Atom	86:Atom	87:Atom	88:Atom	89:Atom	101:CLASS		

=> d 1-6 bib abs hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:42270 CAPLUS
DN 138:89958
TI Preparation of benzothiophene and benzothiazole compounds as cholinergic and monoamine receptor modulators
IN Peters, Dan; Olsen, Gunnar M.; Nielsen, Elsebet Ostergaard; Ahring, Philip K.; Jorgensen, Tino Dyhring
PA Neurosearch A/S, Den.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003004493	A1	20030116	WO 2002-DK460	20020702
	WO 2003004493	C1	20030410		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI DK 2001-1064 A 20010706
OS MARPAT 138:89958
GI



I



II

AB Novel compds. of formula I [A, B, D, E, G = C, N; X = heterocycle] are prepd. that are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacol. profile the compds. of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chem. substances. Thus, was prepd. and inhibited 3H-.alpha.-bungarotoxine binding in rat brain with IC50 of 0.018 .mu.M.

IT **484650-60-4P**
RL: DGN (Diagnostic use); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of benzothiophene and benzothiazole compds. as cholinergic and monoamine receptor modulators)
RN 484650-60-4 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxidobenzo[b]thien-2-yl)- (9CI) (CA INDEX NAME)



IT **484650-61-5P 484650-62-6P 484650-63-7P**
484650-64-8P 484650-65-9P 484651-14-1P

484651-19-6P 484651-20-9P 484651-21-0P
484651-22-1P
RL: DGN (Diagnostic use); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of benzothiophene and benzothiazole compds. as cholinergic and monoamine receptor modulators)

RN 484650-61-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxidobenzo[b]thien-2-yl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 484650-60-4
CMF C15 H15 N O2 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 484650-62-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxidobenzo[b]thien-2-yl)-8-methyl- (9CI) (CA INDEX NAME)



RN 484650-63-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxidobenzo[b]thien-2-yl)-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 484650-62-6
CMF C16 H17 N O2 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.





RN 484650-64-8 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxidobenzo[b]thien-2-yl)-8-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 484650-65-9 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxidobenzo[b]thien-2-yl)-8-ethyl-(9CI) (CA INDEX NAME)



RN 484651-14-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxidobenzo[b]thien-2-yl)-8-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 484651-19-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxido-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 484651-20-9 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxido-2-benzothiazolyl)-8-methyl-(9CI) (CA INDEX NAME)



RN 484651-21-0 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxido-2-benzothiazolyl)-8-ethyl-(9CI) (CA INDEX NAME)



RN 484651-22-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(1,1-dioxido-2-benzothiazolyl)-8-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT **216853-40-6P 484650-70-6P 484650-71-7P 484650-72-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of benzothiophene and benzothiazole compds. as cholinergic and monoamine receptor modulators)

RN 216853-40-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl-8-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 484650-70-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 484650-71-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-benzo[b]thien-2-yl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 484650-72-8 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-(1,1-dioxidobenzo[b]thien-2-yl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:293427 CAPLUS
DN 136:325574
TI Preparation of piperazine, homopiperazine, and 8-azabicyclo[3.2.1]oct-2-ene, and 3,9-diazabicyclo[4.2.1]nonane derivatives for treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
IN Olsen, Gunnar M.; Peters, Dan; Nielsen, Elsebet Ostergaard
PA Neurosearch A/S, Den.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002030405	A2	20020418	WO 2001-DK661	20011010
	WO 2002030405	A3	20020906		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001095436	A5	20020422	AU 2001-95436	20011010
	EP 1358177	A2	20031105	EP 2001-976043	20011010
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	DK 2000-1535	A	20001013		
	US 2000-242146P	P	20001023		
	WO 2001-DK661	W	20011010		

OS MARPAT 136:325574
GI



I

II

AB This invention relates to use of the combined action of a nicotinic acetylcholine receptor agonist and a monoamine reuptake inhibitor for the treatment of affective disorders including depression, anxiety, obsessive compulsive disorder (OCD), panic disorder, or pain, as well as to pharmaceutical compns. comprising these substances and chem. substances for use according to the invention. The chem. substances are represented by piperazine and homopiperazine derivs. (I; n = 1,2,3; m = 0,1,2; R = H, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, acyl, benzyl; R1 = 5-bromo-3-pyridyl, 6-chloro-3-pyridyl, 6-bromo-5-methoxy-3-pyridyl, 6-bromo-3-pyridyl, 6-bromo-5-chloro-3-pyridyl, 5,6-dibromo-3-pyridyl, etc.) and 8-azabicyclo[3.2.1]oct-2-ene derivs. (II; R = H, alkyl, alkenyl, cycloalkyl, cyanoalkyl, Ph, naphthyl, benzyl; R1 = CHO, alkanoyl, cycloalkanoyl, carbamoyl, furanyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, imidazolyl, pyridyl, pyrimidinyl, thiazolyl, naphthyl, indolyl, benzofuranyl, etc.). Thus, 1-(6-Chloro-3-pyridyl)piperazine

(III) (0.3, 1, 3, 10 mg/kg s.c.) was tested in the mouse forced swim test which is considered predictive of a potential antidepressant pharmacol. effect and it did not affect forced swimming with a 30 min pretreatment. However, the combination of venlafaxine and III (1+3; 3+3; 10+1; 10+3 mg/kg s.c.) significantly increased the forced swimming in NMRI mice.

IT **412347-70-7P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; prepn. of piperazine, homopiperazine, azabicyclo[3.2.1]octene, and diazabicyclo[4.2.1]nonane derivs. for treatment of affective disorders)

RN 412347-70-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl- (9CI) (CA INDEX NAME)



IT **273403-42-2P 412347-74-1P 412347-75-2P**
412347-78-5P 412347-80-9P 412347-82-1P
412347-83-2P 412347-86-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of piperazine, homopiperazine, azabicyclo[3.2.1]octene, and diazabicyclo[4.2.1]nonane derivs. for treatment of affective disorders)

RN 273403-42-2 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3,4-dibromo-2-thienyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 412347-74-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl-8-ethyl- (9CI) (CA INDEX NAME)



RN 412347-75-2 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl-8-ethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 412347-74-1
CMF C17 H19 N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 412347-78-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl-8-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 412347-80-9 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)-8-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 412347-82-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-acetonitrile, 3-benzo[b]thien-2-yl- (9CI) (CA INDEX NAME)



RN 412347-83-2 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-acetonitrile, 3-benzo[b]thien-2-yl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 412347-82-1
CMF C17 H16 N2 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 412347-86-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3,4-dibromo-2-thienyl)-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 273403-42-2

CMF C12 H13 Br2 N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT 216853-33-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of piperazine, homopiperazine, azabicyclo[3.2.1]octene, and diazabicyclo[4.2.1]nonane derivs. for treatment of affective disorders)
RN 216853-33-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl-8-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:472712 CAPLUS
DN 135:76800
TI Azabicyclo[3.2.1]octane derivatives with activity as serotonin reuptake inhibitors and 5-HT1A antagonists, and their use as antidepressants.
IN He, John Xiaoqiang; Honigschmidt, Nicholas Allan; Kohn, Todd Jonathan; Rocco, Vincent Patrick; Spinazze, Patrick Gianpietro; Takeuchi, Kumiko
PA Eli Lilly and Co., USA
SO PCT Int. Appl., 97 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001046187	A1	20010628	WO 2000-US32431	20001206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1242419	A1	20020925	EP 2000-982253	20001206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI US 1999-172610P P 19991220
WO 2000-US32431 W 20001206
OS MARPAT 135:76800
GI



I



II

AB The invention provides compds. of formula I [A = H, OH, alkoxy; B = (un)substituted benzothienyl, benzofuranyl, indolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, quinolinyl, phthalazinyl, naphthalenyl, or benzo[h]quinolinyl; X = H, OH, alkoxy, or is absent; Y = CH2, NH, or S; R1 = H, F, alkyl, CONH2 or (di)alkyl derivs., cyano; R2 = H, F, Cl, Br, iodo, OH, alkyl, or alkoxy; p = 0-4; q = 0-3] and their pharmaceutically acceptable salts. The compds. are potent serotonin reuptake inhibitors and antagonists of 5-HT1A receptors (no data). As such, they are expected to be useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. Fourteen synthetic examples and several precursor prepns. are given. For instance, title compd. II was prepd. in 87% yield by reaction of endo-3-(4-methoxybenzo[b]thiophen-2-yl)-8-azabicyclo[3.2.1]octane (prepn. given) with (S)-4-(oxiranylmethoxy)indole in refluxing MeOH.

IT **346465-39-2P 346465-40-5P 346465-42-7P**
346465-43-8P 346465-46-1P 346465-47-2P
346465-48-3P 346465-49-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of azabicyclooctane derivs. as serotonin reuptake inhibitors and 5-HT1A antagonists for use as antidepressants)

RN 346465-39-2 CAPLUS

CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, .alpha.-[(1H-indol-4-yloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-, (.alpha.S,1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346465-40-5 CAPLUS

CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, .alpha.-[(1H-indol-4-yloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-, (.alpha.S,1S,5R)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 346465-39-2
CMF C27 H28 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 346465-42-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, .alpha.-[(1H-indol-4-yloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-, (.alpha.S,1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346465-43-8 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, .alpha.-[(1H-indol-4-yloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-, (.alpha.S,1R,5S)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 346465-42-7
CMF C27 H28 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 346465-46-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, 3-(4-methoxybenzo[b]thien-2-yl)-.alpha.-[[(2-methyl-1H-indol-4-yl)oxy]methyl]-, (.alpha.S,1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346465-47-2 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, 3-(4-methoxybenzo[b]thien-2-yl)-.alpha.-[[(2-methyl-1H-indol-4-yl)oxy]methyl]-, (.alpha.S,1S,5R)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 346465-46-1
CMF C28 H30 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 346465-48-3 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, 3-(4-methoxybenzo[b]thien-2-yl)-.alpha.-[[(2-methyl-1H-indol-4-yl)oxy]methyl]-, (.alpha.S,1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346465-49-4 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, 3-(4-methoxybenzo[b]thien-2-yl)-.alpha.-[[(2-methyl-1H-indol-4-yl)oxy]methyl]-, (.alpha.S,1R,5S)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 346465-48-3
CMF C28 H30 N2 O3 S

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **345995-28-0P 345995-30-4P 345995-31-5P**
346465-83-6P 346465-85-8P 346465-87-0P
346465-90-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of azabicyclooctane derivs. as serotonin reuptake inhibitors and 5-HT1A antagonists for use as antidepressants)

RN 345995-28-0 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-(4-methoxybenzo[b]thien-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 345995-30-4 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(4-methoxybenzo[b]thien-2-yl)- (9CI) (CA INDEX NAME)



RN 345995-31-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(4-methoxybenzo[b]thien-2-yl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 345995-30-4
CMF C16 H17 N O S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 346465-83-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-(4-chloro-2-benzothiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 346465-85-8 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(4-chloro-2-benzothiazolyl)- (9CI) (CA INDEX NAME)



RN 346465-87-0 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-(5-fluoro-2-benzothiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 346465-90-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-(4,5-dimethyl-2-

benzothiazolyl)-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:472711 CAPLUS
DN 135:76778
TI Benzofuran derivatives with activity as serotonin reuptake inhibitors and 5-HT1A antagonists, and their use as antidepressants.
IN He, John Xiaoqiang; Honigschmidt, Nicholas Allan; Kohn, Todd Jonathan; Rocco, Vincent Patrick; Spinazze, Patrick Gianpietro; Takeuchi, Kumiko
PA Eli Lilly and Company, USA
SO PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001046186	A1	20010628	WO 2000-US32425	20001206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1248786	A1	20021016	EP 2000-983784	20001206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003130513	A1	20030710	US 2002-148768	20020909
PRAI	US 1999-172742P	P	19991220		
	WO 2000-US32425	W	20001206		

OS MARPAT 135:76778
GI



I



II

AB The invention provides compds. of formula I [A = H, OH, alkoxy; B =

(un)substituted benzothienyl, benzofuranyl, indolyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, quinolinyl, phthalazinyl, naphthalenyl, or benzo[h]quinolinyl; X = H, OH, alkoxy, or is absent; R, R1 = H, F, alkyl, CONH2 or (di)alkyl derivs., cyano, or R1 is absent; R2 = H, F, Cl, Br, iodo, OH, alkyl, or alkoxy; p = 0-4; q = 0-3] and their pharmaceutically acceptable salts. The compds. are potent serotonin reuptake inhibitors and antagonists of 5-HT1A receptors (no data). As such, they are expected to be useful for treating depression, anxiety, and alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine. Three synthetic examples and several precursor prepns. are given. For instance, title compd. II (as the oxalate) was prepd. in 84% yield by reaction of endo-3-(4-methoxybenzo[b]thiophen-2-yl)-8-azabicyclo[3.2.1]octane (prepn. given) with (2S)-4-(glycidyloxy)benzofuran in refluxing MeOH.

IT **345995-17-7P 345995-18-8P 345995-19-9P 345995-20-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of benzofuran derivs. as serotonin reuptake inhibitors and 5-HT1A antagonists for use as antidepressants)

RN 345995-17-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, .alpha.-[(4-benzofuranyloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-, (.alpha.S,1S,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345995-18-8 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, .alpha.-[(4-benzofuranyloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-, (.alpha.S,1S,5R)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 345995-17-7
CMF C27 H27 N O4 S

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 345995-19-9 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, .alpha.-[(4-

benzofuranyloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-,
(.alpha.S,1R,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 345995-20-2 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-ethanol, .alpha.-[(4-
benzofuranyloxy)methyl]-3-(4-methoxybenzo[b]thien-2-yl)-,
(.alpha.S,1R,5S)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 345995-19-9
CMF C27 H27 N O4 S

Absolute stereochemistry.



CM 2

CRN 144-62-7
CMF C2 H2 O4



IT **345995-28-0P 345995-30-4P 345995-31-5P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of benzofuran derivs. as serotonin reuptake inhibitors and 5-HT1A antagonists for use as antidepressants)
RN 345995-28-0 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene-8-carboxylic acid, 3-(4-methoxybenzo[b]thien-2-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 345995-30-4 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(4-methoxybenzo[b]thien-2-yl)- (9CI) (CA INDEX NAME)



RN 345995-31-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(4-methoxybenzo[b]thien-2-yl)-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 345995-30-4
CMF C16 H17 N O S



CM 2

CRN 144-62-7
CMF C2 H2 O4



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:384193 CAPLUS
DN 133:30663
TI Preparation of 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives as cholinergic ligands at the nicotinic Acetyl Choline Receptors (nAChR)
IN Peters, Dan; Olsen, Gunnar M.; Nielsen, Simon Feldbaek; Nielsen, Elsebet Ostergaard
PA Neurosearch A/S, Den.
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000032600	A1	20000608	WO 1999-DK661	19991126
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2342621	AA	20000608	CA 1999-2342621	19991126
	EP 1133494	A1	20010919	EP 1999-973031	19991126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002531456	T2	20020924	JP 2000-585242	19991126
	AU 761055	B2	20030529	AU 2000-13761	19991126
	NZ 510287	A	20030530	NZ 1999-510287	19991126
	EP 1382605	A2	20040121	EP 2003-22707	19991126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
	US 2002035122	A1	20020321	US 2001-864367	20010525
	US 6680328	B2	20040120		

PRAI DK 1998-1570 A 19981127
EP 1999-973031 A3 19991126
WO 1999-DK661 W 19991126
OS MARPAT 133:30663
GI



I

AB The title compds. [I; R = H, alkyl, alkenyl, etc.; R1 = COR2, (un)substituted mono- or polycyclic aryl, (un)substituted (un)satd. 5-6 membered heterocyclyl, etc.; R2 = H, alkyl, alkenyl, etc.] and their salts which are found to be cholinergic ligands at the nicotinic Acetyl Choline Receptors (no data) and may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neurodegeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chem. substances, were prepd. E.g., a 2-step synthesis of (.+-.)-8-azabicyclo[3.2.1]oct-2-ene I.fumarate [R = Me; R1 = 6-methoxy-2-naphthyl] was given. Compds. I may also be useful as radioligands for in vivo receptor imaging (neuroimaging).

IT **216853-59-7P 273402-98-5P 273403-04-6P**
273403-05-7P 273403-08-0P 273403-09-1P
273403-41-1P 273403-42-2P 273403-43-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 8-azabicyclo[3.2.1]oct-2-ene and -octane derivs. as cholinergic ligands at the nicotinic Acetyl Choline Receptors (nAChR))

RN 216853-59-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 273402-98-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)-8-methyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 216853-59-7
CMF C12 H14 Br N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 273403-04-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)- (9CI) (CA INDEX NAME)



RN 273403-05-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 273403-04-6
CMF C11 H12 Br N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 273403-08-0 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)-8-ethyl- (9CI) (CA INDEX NAME)



RN 273403-09-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)-8-ethyl-, (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 273403-08-0
CMF C13 H16 Br N S





CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 273403-41-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-iodo-2-thienyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 273403-42-2 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3,4-dibromo-2-thienyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 273403-43-3 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3,4-dichloro-2-thienyl)-8-methyl- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:795013 CAPLUS
DN 130:52335
TI 8-Azabicyclo[3.2.1]oct-2-ene and -octane derivatives as cholinergic ligands at nicotinic ACh receptors
IN Peters, Dan; Olsen, Gunnar M.; Nielsen, Simon Feldbaek; Nielsen, Elsebet Ostergaard
PA Neurosearch A/s, Den.
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DT Patent
LA English

this appn

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9854181	A1	19981203	WO 1998-DK225	19980529
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	ZA 9804639	A	19981211	ZA 1998-4639	19980529
	AU 9874261	A1	19981230	AU 1998-74261	19980529
	AU 745964	B2	20020411		
	EP 984965	A1	20000315	EP 1998-921378	19980529
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	EE 9900529	A	20000615	EE 1999-529	19980529
	EE 4057	B1	20030616		
	BR 9809697	A	20000711	BR 1998-9697	19980529
	NZ 500642	A	20011130	NZ 1998-500642	19980529
	JP 2002501514	T2	20020115	JP 1999-500130	19980529
	RU 2186780	C2	20020810	RU 1999-128075	19980529
	NO 9905850	A	19991129	NO 1999-5850	19991129
	US 6645977	B1	20031111	US 1999-450637	19991129
	MX 9911081	A	20000831	MX 1999-11081	19991130
PRAI	DK 1997-627	A	19970530		
	DK 1997-1502	A	19971219		
	DK 1998-408	A	19980324		
	DK 1998-534	A	19980416		
	WO 1998-DK225	W	19980529		

OS MARPAT 130:52335

GI



I

AB Title compds. I (R = H, alkyl, alkenyl, aryl, aralkyl, etc.; R1 = acyl, aryl, heteroaryl, etc.) or their satd. analogs were prepd. by several methods. Thus, endo-8-benzyl-3-hydroxy-3-(3-pyridyl)-8-azabicyclo[3.2.1]octane (II) was prepd. in 34% yield from 8-benzyl-8-azabicyclo[3.2.1]octan-3-one and 3-bromopyridine, and II was then converted to I (R = benzyl, R1 = 3-pyridyl) in 78% yield. The latter was converted to the fumarate salt. The affinity of the products for nicotinic ACh receptors was examd. in tests of 3H-cytisine, 3H-epibatidin, and 3H-.alpha.-bungarotoxin binding.

IT **216853-31-5P 216853-54-2P 216853-60-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(8-azabicyclo[3.2.1]oct-2-ene and -octane derivs. as cholinergic ligands at nicotinic ACh receptors)

RN 216853-31-5 CAPLUS

CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(2-benzofuranyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 216853-54-2 CAPLUS

CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(2-benzofuranyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-53-1
CMF C15 H15 N O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-60-0 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-59-7
CMF C12 H14 Br N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT **216853-09-7P 216853-11-1P 216853-32-6P**
216853-33-7P 216853-40-6P 216853-58-6P
216853-59-7P 216853-62-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(8-azabicyclo[3.2.1]oct-2-ene and -octane derivs. as cholinergic ligands at nicotinic ACh receptors)
RN 216853-09-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 8-methyl-3-(3-quinolinyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-08-6
CMF C17 H18 N2



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-11-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-benzofuranyl)-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-10-0
CMF C16 H17 N O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-32-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(2-benzofuranyl)-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-31-5
CMF C16 H17 N O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-33-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl-8-methyl- (9CI) (CA INDEX NAME)



RN 216853-40-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-2-yl-8-methyl-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216853-58-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(2-benzofuranyl)-8-ethyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-57-5
CMF C17 H19 N O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-59-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-thienyl)-8-methyl- (9CI) (CA INDEX NAME)



RN 216853-62-2 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromo-2-benzofuranyl)-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-61-1
CMF C16 H16 Br N O



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



IT **216853-13-3P 216853-17-7P 216853-42-8P**
216853-43-9P 216853-45-1P 216853-49-5P
216853-51-9P 216853-56-4P 216853-64-4P
216853-66-6P 216853-68-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(8-azabicyclo[3.2.1]oct-2-ene and -octane derivs. as cholinergic ligands at nicotinic ACh receptors)

RN 216853-13-3 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-benzo[b]thien-3-yl-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-12-2
CMF C16 H17 N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-17-7 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 8-methyl-3-(3-thienyl)-, hydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 216853-42-8 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 8-methyl-3-(2-thienyl)-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-41-7
CMF C12 H15 N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-43-9 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-[3-(methoxymethyl)-2-thienyl]-8-methyl-
(9CI) (CA INDEX NAME)



RN 216853-45-1 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(2-benzothiazolyl)-8-methyl-,
(2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-44-0
CMF C15 H16 N2 S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-49-5 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 8-methyl-3-thieno[3,2-b]thien-2-yl-,
ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-48-4
CMF C14 H15 N S2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 216853-51-9 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 8-methyl-3-thieno[2,3-b]thien-2-yl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-50-8
CMF C14 H15 N S2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RN 216853-56-4 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-[3-(3-furanyl)-2-thienyl]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-55-3
CMF C15 H15 N O S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-64-4 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-bromobenzo[b]thien-2-yl)-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-63-3
CMF C16 H16 Br N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-66-6 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-(3-chloro-2-thienyl)-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-65-5
CMF C12 H14 Cl N S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 216853-68-8 CAPLUS
CN 8-Azabicyclo[3.2.1]oct-2-ene, 3-[3-(3-furanyl)-2-thienyl]-8-methyl-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 216853-67-7
CMF C16 H17 N O S



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 1-8 bib abs hitstr

L10 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:696895 CAPLUS
DN **139:214459**
TI Preparation of 5-azolylmethyl oxazolidinones and their use as antibacterial agents
IN Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague, Daniel Robert
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003072576	A2	20030904	WO 2003-GB791	20030225

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-360688P P 20020228
OS MARPAT 139:214459
GI



I



II

AB 3-Cyclyl-5-[(nitrogen-contg. 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[4-(1-Oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[(4-azidomethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is, for example, halo or (1-4C)alkyl that is substituted by 1 substituent =, for example, OH, (1-4C)alkoxy, amino, cyano, azido; Q = for example, 3-R2-4-T-5-R3phenyl wherein R2 and R3 = H or fluoro; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to S) are useful as antibacterial agents; and processes for their manuf. and pharmaceutical compns. contg. them are described. Compds. I have a good spectrum of activity in vitro against std. organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive Staphylococcus aureus and against methicillin resistant and quinolone resistant Staphylococcus aureus are 4 and 8 .mu.g/mL, resp. Compds. I showed a favorable decreased MAO-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azolylmethyl or hydroxymethyl. They also showed favorable decreased MAO-A potency compared with analogs in which the HET group is unsubstituted. Sixty-one example prepns. of I are included. For example, to prep. II, (5R)-3-[4-(1-oxo-3,6-dihydro-2H-

thiopyran-4-yl)-3-fluorophenyl]-5-[(4-hydroxymethyl-1,2,3-triazol-1-yl)methyl]oxazolidin-2-one (2.7 mmol) (prepn. given) was suspended in CH2Cl2 (10 mL), 1,8-diazabicyclo[5.4.0]undec-7-ene (4.7 mmol) was added and the reaction mixt. was cooled to -5.degree.; diphenylphosphoryl azide (3.25 mmol) was added dropwise and it was stirred for 18 h at room temp.; workup gave 1.02 g of II.

L10 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:696894 CAPLUS
DN **139:214458**
TI Preparation of 3-cyclyl-5-[(nitrogen-containing 5-membered ring)methyl]oxazolidinones and their use as antibacterial agents
IN Gravestock, Michael Barry; Hales, Neil James; Reck, Folkert; Zhou, Fei; Fleming, Paul Robert; Carcanague, Daniel Robert; Girardot, Marc Michel
PA Astrazeneca AB, Swed.; Astrazeneca UK Limited
SO PCT Int. Appl., 140 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003072575	A1	20030904	WO 2003-GB785	20030225

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-360957P P 20020228
OS MARPAT 139:214458
GI



I



II

AB 3-Cyclyl-5-[(nitrogen-contg. 5-membered ring)methyl]oxazolidinones (shown as I; e.g. (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-[4-methyl-1,2,3-triazol-1-ylmethyl]oxazolidin-2-one (shown as II); -N-HET is, for example, 3-R1-1,2,4-triazol-1-yl or 5-R1-2H-tetrazol-2-yl wherein R1 is (1-4C)alkyl; Q = for example, 3-R2-4-T-5-R3phenyl wherein R2 and R3 = H or fluoro; T = for example, 5,6-dihydro-2H-thiopyran-4-yl with 0-2 O atoms bonded to S), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolyzable ester thereof, are useful as antibacterial agents; and processes for their manuf. and pharmaceutical compns. contg. them are described. Compds. I have a good spectrum of activity in vitro against std. organisms, which are used to screen for activity against pathogenic bacteria. For example, the min. inhibitory concns. of II against methicillin sensitive and quinolone sensitive Staphylococcus aureus and against methicillin resistant and quinolone resistant Staphylococcus aureus are 2 and 4 .mu.g/mL, resp., compared to 2 and 2 .mu.g/mL for the ref. compd. without the Me substituent. Compds. I showed a favorable

decreased MAO-A potency compared with analogs from the known art with C-5 side chains such as acetamidomethyl or unsubstituted azolylmethyl or hydroxymethyl. They also showed favorable decreased MAO-A potency compared with analogs in which the HET group is unsubstituted. Fifty-seven example prepns. of intermediates and 44 example prepns. of I are included. For example, to prep. II, (5R)-3-[4-(1-oxo-3,6-dihydro-2H-thiopyran-4-yl)-3-fluorophenyl]-5-azidomethyloxazolidin-2-one (1.0 mmol; prepn. described) was mixed with 5,6,7,8-tetrachloro-2,9-dimethyl-1,4-dihydro-1,4-ethenonaphthalene (2.0 mmol) in dry 1,4-dioxane (4 mL) in a sealed microwave reaction tube. The tube was placed in a Smith microwave reactor at 170.degree. for 20 min. The reaction mixt. was then transferred into a round bottom flask and the solvent was removed under vacuum. The residue was purified by chromatog. on silica gel with 5% MeOH in CH2Cl2 to give a mixt. of the 4- and 5-Me regioisomers. This mixt. was further sepd. on a chiral column (chiralcel OD) with iso-PrOH/hexanes (1:1) to give II (74 mg).

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:927428 CAPLUS
DN **138:14010**
TI Preparation of aryl-8-azabicyclo[3.2.1]octanes for the treatment of depression
IN Gilbert, Adam Matthew
PA Wyeth, John, and Brother Ltd., USA
SO PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002096906	A1	20021205	WO 2002-US16008	20020520
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003032645	A1	20030213	US 2002-151210	20020520
	US 6632824	B2	20031014		
PRAI	US 2001-293563P	P	20010525		

OS MARPAT 138:14010
GI



I



II

AB Title compds. I [X = NH, O or S; Y = (CH2)n where n = 0-3; A = (un)-substituted Ph or -pyridyl ring with addnl. possibility of being fused to an addnl. cycloalkyl or heterocyclic group using the ortho and meta positions; Ar = (un)substituted -indolyl, -Ph, -naphthyl, -anthracenyl, -phenanthrenyl, -benzyl, -benzofuryl, or -benzothienyl] are prepd. and disclosed as compds. for the treatment of depression. Thus, II was prepd. by N-alkylation of 3-naphththalen-2-yl-8-azabicyclo[3.2.1]oct-2-ene (prepn. given) with 4-(2-chloroethoxy)-1H-indole (prepn. given). I possessed IC50 values (nM) in the range of 3.5-191.0 in binding assays with cells possessing the human 5-HT transporter. The invention also

includes formulations contg. these compds., and methods for making and using compds. of this invention.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:754196 CAPLUS
DN **137:257677**
TI Methods of treating or preventing Alzheimer's disease using 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes
IN Nieman, James A.; Fang, Lawrence; Jagodzinska, Barbara
PA Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SO PCT Int. Appl., 449 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076440	A2	20021003	WO 2002-US9100	20020321
WO 2002076440	A3	20021128		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-278371P P 20010323
US 2001-308729P P 20010730
OS MARPAT 137:257677
GI



I

AB Disclosed are methods for treating or preventing Alzheimer's disease, and other diseases, and/or inhibiting .beta.-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, using 3,4-disubstituted piperidinyl compds. (I) wherein the variables R1, R2, R3, R4, Q, W, X, Z, m, and n are defined below. Although neither the compds. nor the methods of prepn. are claimed, .apprx.150 example prepns., translations from the German examples of patent WO 9709311, are included. I inhibit .beta.-secretase with IC50 < 50 .mu.M; compds. that are effective inhibitors of .beta.-secretase activity demonstrate reduced cleavage of the substrate as compared to a control. In I, R1 is aryl, heterocycle; R2 is Ph, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diazinyl, triazolyl, thienyl, oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, or furyl, optionally substituted. R3 is: H, hydroxy, lower-alkoxy, or lower-alkenyloxy; R4 is: H, lower-alkyl, lower-alkenyl, lower-alkoxy, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, benzyl, oxo, or where R3 and R4 together are a bond, or as specified in the claims. Q is: ethylene, or is absent; X is: a bond, -O-, -S-, -CH-R11- (R11 defined in claims), -CHOR9- (R9 defined in claims), -OCO, -CO-, or C:NOR10- (R10 is carboxyalkyl, alkoxycarbonylalkyl, alkyl or H), with the bond emanating from an O or S atom joining to a satd. C atom of group Z or to R1; W is: -O-, or -S-; Z is: lower-alkylene, lower-alkenylene, hydroxy-lower-alkylidene, -O-, -S-, -O-Alk- (Alk is a lower alkylene), -S-Alk-, -Alk-O-, or -Alk-S. N is: 1, or 0 or 1 when X is -O-CO; and where m is 0 or 1; with provisos.

L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:811082 CAPLUS
DN **132:49887**
TI Preparation of 3-(bicyclic-heteroaryl)-8-azabicyclo[3.2.1]oct-2-enes and -octanes for inhibition of serotonin reuptake
IN Audia, James Edmund; McDaniel, Stacey Leigh; Nissen, Jeffrey Scott

10/620559

PA Eli Lilly and Company, USA
SO PCT Int. Appl., 46 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9965492	A1	19991223	WO 1999-US12602	19990604
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2335336	AA	19991223	CA 1999-2335336	19990604
AU 9948190	A1	20000105	AU 1999-48190	19990604
JP 2002518331	T2	20020625	JP 2000-554372	19990604
US 6107307	A	20000822	US 1999-326924	19990607
EP 969005	A1	20000105	EP 1999-304680	19990616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRAI US 1998-89951P P 19980619
WO 1999-US12602 W 19990604
OS MARPAT 132:49887
GI



AB The invention provides 3-(bicyclic-heteroaryl)-8-azabicyclo[3.2.1]oct-2-enes and -octanes I, which are useful for the inhibition of serotonin reuptake in mammals [wherein A-B = C:CH or CHCH2; R = H, or C1-C4 substituent; Het = bicyclic heteroaryl optionally substituted with 1-2 of H, halo, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 alkoxy, cyano, nitro, carboxamido, CF3, or OH; and pharmaceutically acceptable salts thereof]. The compds. are selective inhibitors of serotonin reuptake, and as such are useful as antidepressants, etc. Prepns. of several compds. I and intermediates (some prophetic) are given. For instance, condensation of 6-fluoroindole with tropinone in AcOH in the presence of H3PO4, and hydrogenation of the resultant azabicyclooctene deriv., gave azabicyclooctane deriv. II. In a paroxetine binding assay, representative compds. I inhibited serotonin reuptake potently, with activity in some cases in the low nanomolar range (no addnl. data).
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:708819 CAPLUS
DN **129:316150**
TI Preparation of bicyclic amine derivatives as pesticides
IN Godfrey, Christopher Richard Ayles; Salmon, Roger; Russell, Charles Adam
PA Zeneca Ltd., UK
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9846600	A1	19981022	WO 1998-GB693	19980304
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	AU 9865077	A1	19981111	AU 1998-65077	19980304
	EP 971918	A1	20000119	EP 1998-910848	19980304
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2001521514	T2	20011106	JP 1998-543575	19980304
	ZA 9802204	A	19980928	ZA 1998-2204	19980316
PRAI	GB 1997-6222	A	19970326		
	WO 1998-GB693	W	19980304		

OS MARPAT 129:316150

GI

Ar I

AB The title compds. [I; A = WXCCYZ, XC:CY; Ar = (un)substituted Ph, (un)substituted 5- or 6-membered unsatd., (benzo-fused) heterocyclyl with 1-3 N, O, S; R = H, CHO, cyano, (un)substituted C1-15 alkyl, aryl, aralkyl, (hetero)aryl, (aryl)alkenyl, etc., a proviso is given; W, X, Y, Z = H, OH, acyloxy, alkoxy, alkylsilyloxy, cyano, halo], useful as insecticides, acaricides and nematocides, were prepd. by dehydration of the parent aryl heterocyclyl alcs. For example, adding a THF soln. of 8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octan-3-one to lithiated 3.5-dibromopyridine in THF at -78.degree. and stirring the mixt. for 2 h at -60.degree. gave exo-3-(5-bromopyrid-3-yl)-endo-3-hydroxy-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]octane. This was dissolved in CH2Cl2, stirred with Et3N and MeSO2Cl under N for 1 h at 0.degree. and allowed to react at ambient temp. for .apprx.3 days to give a title compd. 3-(5-bromopyrid-3-yl)-8-(2,2,2-trifluoroethyl)-8-azabicyclo[3.2.1]oct-2-ene. The latter at 500 ppm gave 80-100% kill in a test against Tetranychus urticae. An emulsifiable conc., wettable powder, dusting powder, concd. liq., capsule suspension, aq. suspension conc. and H2O-dispersible granule formulation contg. 3-(6-chloropyrid-3-yl)-8-methyl-8-azabicyclo[3.2.1]oct-2-ene were given.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:372147 CAPLUS
DN **126:343505**
TI Preparation of 8-azabicyclo[3.2.1]oct-2-enes as serotonin reuptake inhibitors
IN Moldt, Peter; Scheel-Krueger, Joergen; Olsen, Gunnar M.; Nielsen, Elsebet Oestergaard
PA Neurosearch A/s, Den.; Moldt, Peter; Scheel-Krueger, Joergen; Olsen, Gunnar M.; Nielsen, Elsebet Oestergaard
SO PCT Int. Appl., 29 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9713770	A1	19970417	WO 1996-EP4449	19961011
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI				
	CA 2233541	AA	19970417	CA 1996-2233541	19961011
	CA 2233541	C	20020430		
	AU 9672917	A1	19970430	AU 1996-72917	19961011
	AU 709327	B2	19990826		
	EP 859777	A1	19980826	EP 1996-934662	19961011
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI				

	CN 1199400	A	19981118	CN 1996-197566	19961011
	CN 1083840	B	20020501		
	JP 10512589	T2	19981202	JP 1997-514726	19961011
	JP 3462505	B2	20031105		
	BR 9610960	A	19990302	BR 1996-10960	19961011
	CZ 285093	B6	19990512	CZ 1998-758	19961011
	RU 2157372	C2	20001010	RU 1998-105169	19961011
	EE 3446	B1	20010615	EE 1998-62	19961011
	PL 185357	B1	20030430	PL 1996-326195	19961011
	SK 283425	B6	20030701	SK 1998-287	19961011
	NO 9800919	A	19980608	NO 1998-919	19980303
	US 6100275	A	20000808	US 1998-43294	19980518
PRAI	DK 1995-1156	A	19951013		
	WO 1996-EP4449	W	19961011		

OS MARPAT 126:343505

GI



I

AB Title compds. [I; R = H, (cyclo)alkyl, CH2CH2OH, etc.; R1 = (un)substituted Ph, -naphthyl, -heteroaryl, etc.] were prepd. Thus, 8-methyl-8-azabicyclo[3.2.1]octan-3-one was condensed with 3,4-Cl2C6H3Br and the product dehydrated to give I (R = Me, R1 = C6H3Cl2-3,4). Data for biol. activity of 1 prepd. I were given.

L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1997:307688 CAPLUS

DN **126:277402**

TI New 4-aryl-3-aralkoxypiperidines and -azabicyclooctanes for treating heart and kidney insufficiency

IN Binggeli, Alfred; Breu, Volker; Bur, Daniel; Fischli, Walter; Gueller, Rolf; Hirth, Georges; Maerki, Hans-Peter; Mueller, Marcel; Oefner, Christian; Stadler, Heinz; Vieira, Eric; Wilhelm, Maurice; Wostl, Wolfgang

PA F. Hoffmann-La Roche Ag, Switz.

SO PCT Int. Appl., 492 pp.
CODEN: PIXXD2

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9709311	A1	19970313	WO 1996-EP3803	19960829
	W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, TR				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2230931	AA	19970313	CA 1996-2230931	19960829
	AU 9667432	A1	19970327	AU 1996-67432	19960829
	AU 708616	B2	19990805		
	EP 863875	A1	19980916	EP 1996-927715	19960829
	EP 863875	B1	20030604		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1202152	A	19981216	CN 1996-197674	19960829
	JP 11500447	T2	19990112	JP 1996-510837	19960829
	BR 9610385	A	19990706	BR 1996-10385	19960829
	NZ 315677	A	20000228	NZ 1996-315677	19960829
	RU 2167865	C2	20010527	RU 1998-106388	19960829
	AT 242213	E	20030615	AT 1996-927715	19960829
	CZ 292327	B6	20030917	CZ 1998-684	19960829
	ZA 9607424	A	19970307	ZA 1996-7424	19960902
	TW 474932	B	20020201	TW 1996-85110684	19960902
	NO 9800954	A	19980428	NO 1998-954	19980305
	US 6051712	A	20000418	US 1999-255185	19990222
	US 6150526	A	20001121	US 1999-456283	19991207
PRAI	CH 1995-2548	A	19950907		
	CH 1996-1876	A	19960726		
	WO 1996-EP3803	W	19960829		
	US 1996-711339	A3	19960906		
	US 1999-255185	A1	19990222		

OS MARPAT 126:277402

GI



I

AB New piperidine and azabicyclooctane derivs. (> 1000 compds.) are renin inhibitors for treatment of high blood pressure, heart and kidney insufficiency. Thus, the piperidine deriv. I was prepd. from 1-benzyl-3-propyl-4-piperidinone by reaction with 4-FC6H4Br, followed by 1-benzyloxy-3-chloromethylnaphthalene and deblocking. I had a renin-inhibiting IC50 of 0.317 .mu.M.